Reported about 15 hours ago
Ionis Pharmaceuticals has administered the first dose to a participant in the Phase 3 REVEAL trial for ION582, focusing on treating Angelman syndrome, a severe neurodevelopmental disorder. The study will involve around 200 individuals with UBE3A gene abnormalities and aims to assess improvements in expressive communication over 52 weeks using doses of ION582. The trial is based on earlier positive results and will complete enrollment by 2026.
Source: YAHOO